|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase显示文摘包含 methyltransferase 建筑群的象 3 一样的 methyltransferase (METTL3 ) 催化 N6-methyladenosine (m6A ) 形成,一个新奇 epitranscriptomic 标记;然而,这建筑群的性质仍然保持大部分未知。这里,我们报导人的 m6A methyltransferase 建筑群, Wilm 的肿瘤 1 伙伴蛋白质(WTAP ) 和象 14 一样的 methyltransferase (METTL14 ) 的二个新部件。WTAP 与 METTL3 和 METTL14 交往,并且为他们的本地化被要求进在 vivo 与处理因素的 pre-mRNA 并且为 m6A methyltransferase 的催化活动充实的原子点缀。RNA 的多数在 vivo 由 WTAP 和 METTL3 跳了代表包含一致 m6A 主题的 mRNAs。当 WTAP 不在时, METTL3 的 RNA 有约束力的能力强烈被减少,建议 WTAP 可以工作调整到 mRNA 目标的 m6A methyltransferase 建筑群的招募。而且,在有 photoactivatable-ribonucleoside-enhanced crosslinking 和 immunoprecipitation (同等片断) 的联合的 transcriptomic 分析说明那 WTAP 和 METTL3 调整涉及抄写并且 RNA 处理的基因拼接的表示和选择。在 zebrafish 胚胎的调停 Morpholino 的击倒的指向 WTAP 或 METTL3 引起了织物区别缺点并且增加了 apoptosis。这些调查结果提供 WTAP 可以在 m6A methyltransferase 建筑群作为一个规章的子单元工作并且在 RNA 的 epitranscriptomic 规定起一个关键作用的充分证据新陈代谢。 | Xiao-Li Ping Bao-Fa Sun Lu Wang Wen Xiao Xin Yang Wen-Jia Wang Samir Adhikari Yue Shi Ying Lv Yu-Sheng Chen Xu Zhao Ang Li Ying Yang Ujwal Dahal Xiao-Min Lou Xi Liu Jun Huang Wei-Ping Yuan Xiao-Fan Zhu Tao Cheng Yong-Liang Zhao Xinquan Wang Jannie M Rendtlew Danielsen Feng Liu Yun-Gui Yang | 2014 | Cell Research2014，24，2： | 244 |
| 2 | FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis显示文摘 | Xu Zhao Ying Yang Bao-Fa Sun Yue Shi Xin Yang Wen Xiao Ya-Juan Hao Xiao-Li Ping Yu-Sheng Chen Wen-Jia Wang Kang-Xuan Jin Xing Wang Chun-Min Huang Yu Fu Xiao-Meng Ge Shu-Hui Song Hyun Seok Jeong Hiroyuki Yanagisawa Yamei Niu Gui-Fang Jia Wei Wu Wei-Min Tong Akimitsu Okamoto Chuan He Jannie M Rendtlew Danielsen Xiu-Jie Wang Yun-Gui Yang | 2014 | Cell Research2014，24，12： | 109 |
| 3 | Cytoplasmic m6A reader YTHDF3 promotes mRNA translation显示文摘 | Ang Li Yu-Sheng Chen Xiao-Li Ping Xin Yang Wen Xiao Ying Yang Hui-Ying Sun Qin Zhu Poonam Baidya Xing Wang Devi Prasad Bhattarai Yong-Liang Zhao Bao-Fa Sun Yun-Gui Yang | 2017 | Cell Research2017，27，3： | 82 |
| 4 | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)显示文摘In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named '2019 novel coronavirus(2019-nCoV)' by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV. | Ying-Hui Jin Lin Cai Zhen-Shun Cheng Hong Cheng Tong Deng Yi-Pin Fan Cheng Fang Di Huang Lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui Li Yi-Rong Li Ke Liang Li-Kai Lin Li-Sha Luo Jing Ma Lin-Lu Ma Zhi-Yong Peng Yun-Bao Pan Zhen-Yu Pan Xue-Qun Ren Hui-Min Sun Ying Wang Yun-Yun Wang Hong Weng Chao-Jie Wei Dong-Fang Wu Jian Xia Yong Xiong Hai-Bo Xu Xiao-Mei Yao Yu-Feng Yuan Tai-Sheng Ye Xiao-Chun Zhang Ying-Wen Zhang Yin-Gao Zhang Hua-Min Zhang Yan Zhao Ming-Juan Zhao Hao Zi Xian-Tao Zeng Yong-Yan Wang Xing-Huan Wang 无 | 2020 | Military Medical Research2020，7，1： | 161 |
| 5 | Western North Pacific Tropical Cyclone Database Created by the China Meteorological Administration显示文摘This paper describes the access to, and the content, characteristics, and potential applications of the tropical cyclone(TC) database that is maintained and actively developed by the China Meteorological Administration, with the aim of facilitating its use in scientific research and operational services. This database records data relating to all TCs that have passed through the western North Pacific(WNP) and South China Sea(SCS) since 1949. TC data collection has expanded over recent decades via continuous TC monitoring using remote sensing and specialized field detection techniques,allowing collation of a multi-source TC database for the WNP and SCS that covers a long period, with wide coverage and many observational elements. This database now comprises a wide variety of information related to TCs, such as historical or real-time locations(i.e., best track and landfall), intensity, dynamic and thermal structures, wind strengths, precipitation amounts, and frequency. This database will support ongoing research into the processes and patterns associated with TC climatic activity and TC forecasting. | Xiaoqin LU Hui YU Ming YING Bingke ZHAO Shuai ZHANG Limin LIN Lina BAI Rijin WAN | 2021 | Advances in Atmospheric Sciences2021，38，4： | 96 |
| 6 | Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors显示文摘 | Jing Liao Zhao Wu Ying Wang Lu Cheng Chun Cui Yuan Gao Taotao Chen Lingjun Rao Siye Chen Nannan Jia Huiming Dai Shunmei Xin Jiuhong Kang Gang Pei Lei Xiao | 2008 | Cell Research2008，18，5： | 61 |
| 7 | 5-methylcytosine promotes mRNA export--NSUN2 as the methyltransferase and ALYREF as an m5C reader显示文摘 | Yang, Xin Yang, Ying Sun, Bao-Fa Chen, Yu-Sheng Xu, Jia-Wei Lai, Wei-Yi Li, Ang Wang, Xing Bhattarai, Devi Prasad Xiao, Wen Sun, Hui-Ying Zhu, Qin Ma, Hai-Li Adhikari, Samir Sun, Min Hao, Ya-Juan Zhang, Bing Huang, Chun-Min Huang, Niu Jiang, Gui-Bin Zhao, Yong-Liang Wang, Hai-Lin Sun, Ying-Pu Yang, Yun-Gui | 2017 | Cell Research2017，27，5： | 62 |
| 8 | 2018 Chinese Pediatric Cardiology Society(CPCS) guideline for diagnosis and treatment of syncope in children and adolescents显示文摘Syncope belongs to the transient loss of consciousness(TLOC), characterized by a rapid onset, short duration, and spontaneous complete recovery. It is common in children and adolescents, accounting for 1% to 2% of emergency department visits.Recurrent syncope can seriously affect children's physical and mental health, learning ability and quality of life and sometimes cardiac syncope even poses a risk of sudden death. The present guideline for the diagnosis and treatment of syncope in children and adolescents was developed for guiding a better clinical management of pediatric syncope. Based on the globally recent development and the evidence-based data in China, 2018 Chinese Pediatric Cardiology Society(CPCS) guideline for diagnosis and treatment of syncope in children and adolescents was jointly prepared by the Pediatric Cardiology Society, Chinese Pediatric Society, Chinese Medical Association(CMA)/Committee on Pediatric Syncope, Pediatricians Branch, Chinese Medical Doctor Association(CMDA)/Committee on Pediatric Cardiology, Chinese College of Cardiovascular Physicians, Chinese Medical Doctor Association(CMDA)/Pediatric Cardiology Society, Beijing Pediatric Society, Beijing Medical Association(BMA). The present guideline includes the underlying diseases of syncope in children and adolescents, the diagnostic procedures, methodology and clinical significance of standing test and headup tilt test, the clinical diagnosis vasovagal syncope, postural orthostatic tachycardia syndrome, orthostatic hypotension and orthostatic hypertension, and the treatment of syncope as well as follow-up. | Cheng Wang Yaqi Li Ying Liao Hong Tian Min Huang Xiangyu Dong Lin Shi Jinghui Sun Hongfang Jin Junbao Du Jindou An Jie Chen Mingwu Chen Qi Chen Sun Chen Yonghong Chen Zhi Chen Adolphus Kai-tung Chau Junbao Du Zhongdong Du Junkai Duan Hongyu Duan Xiangyu Dong Lin Feng Lijun Fu Fangqi Gong Yonghao Gui Ling Han Zhenhui Han Bing He Zhixu He Xiufen Hu Yimin Hua Guoying Huang Min Huang Ping Huang Yujuan Huang Hongfang Jin Mei Jin Bo Li Fen Li Tao Li Xiaohui Li Xiaoyan Liu Yan Li Haitao Lv Tiewei Lv Zipu Li Luyi Ma Silin Pan Yusheng Pang Hua Peng Yuming Qin Jie Shen Lin Shi Kun Sun Jinghui Sun Hong Tian Jie Tian Cheng Wang Hong Wang Lei Wang Jinju Wang Wendi Wang Yuli Wang Rongzhou Wu Tianhe Xia Yanyan Xiao Chunhong Xie Yanlin Xing Zhenyu Xiong Baoyuan Xu Yi Xu Hui Yan Shiwei Yang Qijian Yi Xia Yu Xianyi Yu Yue Yuan Hongyan Zhang Huili Zhang Li Zhang Qingyou Zhang Xi Zhang Yanmin Zhang Zhiwei Zhang Cuifen Zhao Bin Zhou Hua Zhu | 2018 | Science Bulletin2018，63，23： | 54 |
| 9 | XA23 Is an Executor R Protein and Confers Broad-Spectrum Disease Resistance in Rice显示文摘 | Chunlian Wang Xiaoping Zhang Yinglun Fan Ying Gao Qinlong Zhu Chongke Zheng Tengfei Qin Yanqiang Li Jinying Che Mingwei Zhang Bing Yang Yaoguang Liu Kaijun Zhao | 2015 | Molecular Plant2015，8，2： | 55 |
| 10 | Ideal cardiovascular health and incidence of atherosclerotic cardiovascular disease among Chinese adults:the China-PAR project显示文摘Existing evidence on the relationship between cardiovascular health(CVH) metrics and cardiovascular disease(CVD) was primarily derived from western populations. We aimed to evaluate the benefits of ideal CVH metrics on preventing incident atherosclerotic CVD(ASCVD) in Chinese population. This study was conducted among 93,987 adults from the China-PAR project(Prediction for ASCVD Risk in China) who were followed up until 2015. Cox proportional hazard regression models were used to estimate the hazard ratios(HRs) and their corresponding 95% confidence intervals(CIs) of CVH metrics for the risk of ASCVD, including coronary heart disease(CHD), stroke and ASCVD death. We further estimated the population-attributable risk percentage(PAR%) of these metrics in relation to each outcome. We observed gradient inverse associations between the number of ideal CVH metrics and ASCVD incidence. Compared with participants having ≤2 ideal CVH metrics, the multivariable-adjusted HRs(95% CIs) of ASCVD for those with 3, 4, 5, 6 and 7 ideal CVH metrics were 0.83(0.74–0.93), 0.66(0.59–0.74), 0.55(0.48–0.61), 0.44(0.38–0.50) and 0.24(0.18–0.31), respectively(P for trend <0.0001). Approximately 62.1% of total ASCVD, 38.7% of CHD, 66.4% of stroke, and 60.5% of ASCVD death were attributable to not achieving all the seven ideal CVH metrics. After adjusting effects of ideal health factors, having four ideal health behaviors could independently bring adults health benefits in preventing 17.4% of ASCVD, 18.0% of CHD, 16.7% of stroke, and 10.1% of ASCVD death. Among all the seven CVH metrics, to keep with ideal blood pressure(BP) implied the largest public health gains against various ASCVD events(PAR% between 33.0% and 47.2%), while ideal diet was the metric most difficult to be achieved in the long term. Our study indicates that the more ideal CVH metrics adults have, the less ASCVD burden there is in China. Special efforts of health education and behavior modification should be made on keeping ideal BP and dietary habits in general Chinese population to prevent the epidemic of ASCVD. | Chao Han Fangchao Liu Xueli Yang Jichun Chen Jianxin Li Jie Cao Ying Li Chong Shen Ling Yu Zhendong Liu Xianping Wu Liancheng Zhao Dongshen Hu Xiangfeng Lu Xigui Wu Dongfeng Gu | 2018 | Science China(Life Sciences)2018，61，5： | 60 |
| 11 | Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment显示文摘Objective:Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor,fibroblast growth factor receptor,platelet-derived growth factor receptor,c-Kit,and c-MET;therefore,it exhibits both antitumor and anti-angiogenetic activities.A phase III trial has shown that anlotinib improved progression-free survival(PFS)and overall survival(OS)in patients with advanced non-small cell lung cancer(NSCLC),who presented with progressive disease or intolerance after standard chemotherapy.This study aimed to analyze the characteristics of patients receiving anlotinib treatment to determine the dominant populations who are fit for the treatment.Methods:Data were collected from March 2015 to January 2017 from a randomized,double-blind,placebo-controlled,multicenter,phase III trial of anlotinib(ALTER0303).A total of 437 patients were enrolled and randomly allocated(2:1)to the anlotinib and placebo groups.Kaplan–Meier analysis and log-rank test were performed to compare PFS and OS.Cox proportional hazards model was adopted for multivariate prognostic analysis.Results:Multivariate analysis indicated that high post-therapeutic peripheral blood granulocyte/lymphocyte ratio and elevated alkaline phosphatase levels were independent risk factors for PFS.Meanwhile,elevated thyroid-stimulating hormone,blood glucose,and triglyceride levels;hypertension;and hand–foot syndrome were independent protective factors of PFS.High posttherapeutic peripheral blood granulocyte/lymphocyte ratio,an Eastern Cooperative Oncology Group(ECOG)score≥2,and the sum of the maximal target lesion length at baseline were independent risk factors of OS,and hypertriglyceridemia was an independent protective factor of OS.Conclusions:This study preliminarily explored the possible factors that affected PFS and OS after anlotinib treatment in patients with advanced refractory NSCLC,and the baseline characteristics of the therapeutically dominant populations were then identified. | Jing Wang Yizhuo Zhao Qiming Wang Li Zhang Jianhua Shi Zhehai Wang Ying Cheng Jianxing He Yuankai Shi Hao Yu Yang Zhao Weiqiang Chen Yi Luo Xiuwen Wang Kejun Nan Faguang Jin Jian Dong Baolan Li Zhujun Liu Baohui Han Kai Li | 2018 | Cancer Biology & Medicine2018，15，4： | 46 |
| 12 | Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis显示文摘背景 endoscopic 以后后退 cholangiopancreatography 胰腺炎(锐气) 被认为是之一使人烦恼的复杂并发症内视镜后退 cholangiopancreatography (ERCP ) 。在锐气上评估 ulinastatin 和 gabexate mesylate (美国通用汽车公司) 的预防效果的使随机化的控制试用的结果是矛盾的。现在的学习被设计与使随机化的控制试用(RCT ) 的元分析在锐气上评估 ulinastatin 和美国通用汽车公司的预防效果 .Methods 五个电子数据库被在找在锐气上评估 ulinastatin 和美国通用汽车公司的预防效果的 RCT。概括效果被估计,方法由 Cochrane Collaboration.Results 推荐了包含 5105 个参加者的 12 研究在我们的元分析被包括。ulinastatin 的管理减少了仅仅在足够的剂量的锐气的发生(或, 0.39;95% CI, 0.19 ~ 0.81;P=0.01 ) 。需要到对待(NNT ) 的数字是 6。并且 ulinastatin 的管理也减少了 post-ERCP hyperamylasemia (PEHA ) 的发生(或, 0.40;95% CI, 0.28 ~ 0.58;P < 0.000 01 ) 。高剂量的美国通用汽车公司的慢注入为锐气预防是有效的(或, 0.44; 95% CI, 0.25 ~ 0.79;P=0.006 ) ,并且低剂量的美国通用汽车公司的快速的注入也为锐气预防显示出功效(或, 0.37; 95% CI, 0.20 ~ 0.69;P=0.002 ) 。NNT 分别地是 7 和 6。然而,在低剂量并且由慢注入的美国通用汽车公司的管理是无效的(或, 0.99;95% CI, 0.64 ~ 1.55;P=0.98 ) 。美国通用汽车公司的管理有趋势减少 PEHA 率,然而并非到统计意义(或, 0.86;95% CI, 0.73 ~ 1.01;P=0.06 ) 。当低质量的研究被排除时,有二高质量的研究的元分析显示 ulinastatin 没减少锐气的率(或, 0.63;95% CI, 0.32 ~ 1.26;P=0.19 ) 并且 PEHA 发生(或, 0.80;95% CI, 0.31 ~ 2.07;P=0.64 ) 。有六高质量的研究的元分析证明美国通用汽车公司管理减少了锐气发生(或, 0.52;95% CI, 0.29 ~ 0.91; P=0.02 ) 不为 PEHA 预防是有效的(或, 0.88;95% CI, 0.74 ~ 1.04;P=0.12 ).Conclusions Ulinastatin 和美国通用汽车公司可能具有为锐气的预防的价值。美国通用汽车公司应该在高剂量并且由快速的注入被管理。并且 ulinastatin 的剂量应该是足够的。然而,结论不是 overwhelming.More 大样品的尺寸和高质量的 RCT 仍然被需要阐明二药的政府是否确实穿上预防效果锐气。 | ZHANG Zhi-feng YANG Ning ZHAO Gang ZHU Lei ZHU Ying WANG Li-xia | 2010 | Chinese Medical Journal2010，，18： | 38 |
| 13 | Current Trends of the Prevalence of Childhood Asthma in Three Chinese Cities: A Multicenter Epidemiological Survey显示文摘Objective To analyze the prevalence of asthma and asthma related symptoms among children aged 0-14 years in three Chinese cities and to obtain a crude estimation of the trend of childhood asthma prevalence in China. Methods A cross-sectional, population-based survey of prevalence of asthma was conducted in children aged from 0 to 14 years in 3 major cities of China (Beijing, Chongqing, and Guangzhou) with different geographic locations. All the subjects were randomly selected by a multi-stage sampling method. Three to five schools and kindergartens in 2 urban districts in each city were randomly selected for the survey, and a validated questionnaire that included the core questions of the International Study of Asthma and Allergies in Childhood, Phase Ⅲ questionnaire and several additional questions were used. All questionnaires were completed by parents or guardians of the selected children. Children whose parents responded affirmatively to the question' Has your child ever been diagnosed as asthma by a doctor' were recognized as victims of asthma. Results The prevalence of asthma in Beijing, Chongqing, and Guangzhou was 3.15%, 7.45%, and 2.09%, respectively. These values were significantly higher than those obtained 10 years ago in the national epidemiological survey in 2000 which used the same method of investigation and the same diagnotic criteria (χ2 =3.938, P=0.047; χ2 =73.506, P≤0.001; χ2 =11.956, P=0.001, in each city). Of the asthmatic children 57.21%, 69.91%, and 60.00% had their first attack before the age of 3 in Beijing, Chongqing, and Guangzhou, respectively. Wheezing was the primary clinical manifestation for all asthmatic children , followed by persistent cough and repeated respiratory infections. Both the prevalence of asthma and asthma-related symptoms were statistically higher in males than in females. Conclusion The prevalence of childhood asthma is statistically higher than that 10 years ago in the three Chinese cities. | JUAN BAI JiNG ZHAO KUN-LING SHEN LI XIANG AI-HUAN CHEN SUI HUANG YING HUANG JIAN-SHENG WANG RONG-WEI YE | 2010 | Biomedical and Environmental Sciences2010，23，6： | 37 |
| 14 | Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy显示文摘Although many studies have investigated intensity-modulated radiation therapy (IMRT) for nasopharyngeal carcinoma (NPC),sample sizes in the reported studies are usually small and different in outcomes in different T and N subgroups are seldom analyzed.Herein,we evaluated the outcomes of NPC patients treated with IMRT and further explored treatment strategy to improve such outcome.We collected clinical data of 865 NPC patients treated with IMRT alone or in combination with chemotherapy,and classified all cases into the following prognostic categories according to different TNM stages:early stage group (T1-2N0-1M0),advanced local disease group (T3-4N0-1M0),advanced nodal disease group (T1-2N2-3M0),and advanced locoregional disease group (T3-4N2-3M0).The 5-year overall survival (OS),local relapse-free survival (LRFS),and distant metastases-free survival (DMFS) were 83.0%,90.4%,and 84.0%,respectively.The early disease group had the lowest treatment failure rate,with a 5-year OS of 95.6%.The advanced local disease group and advanced nodal disease group had similar failure pattern and treatment outcomes as well as similar hazard ratios for death (4.230 and 4.625,respectively).The advanced locoregional disease group had the highest incidence of relapse and death,with a 5-year DMFS and OS of 62.3% and 62.2%,respectively,and a hazard ratio for death of 10.402.Comparing with IMRT alone,IMRT in combination with chemotherapy provided no significant benefit to locoregionally advanced NPC.Our results suggest that the decision of treatment strategy for NPC patients should consider combinations of T and N stages,and that IMRT alone for early stage NPC patients can produce satisfactory results.However,for advanced local,nodal,and locoregional disease groups,a combination of chemotherapy and radiotherapy is recommended. | Sheng-Fa Su 1,2,3,Fei Han 1,2,Chong Zhao 1,2,Ying Huang 1,2,Chun-Yan Chen 1,2,Wei-Wei Xiao 1,2,Jia-Xin Li 1,2 and Tai-Xiang Lu 1,2 1 State Key Laboratory of Oncology in South China,Guangzhou,Guangdong 510060,P.R.China 2 Department of Radiation Oncology,Sun Yat-sen University Cancer Center,Guangzhou,Guangdong 510060,P.R.China 3 Department of Oncology,Guiyang Medical College Hospital,Tumor Hospital of Guizhou,Guiyang,Guizhou 550003,P.R.China. | 2011 | Chinese Journal of Cancer2011，30，8： | 40 |
| 15 | Immunohistochemical study on p53,H-rasp21,c-erbB-2 protein and PCNA expression in HCC tissues of Hart and minority ethnic patients显示文摘AIM To find out the difference of humanprimary liver carcinogenesis between Han andminority ethnic patients in Xinjiang.METHODS Expression of p53,c-erbB-2,H-rasp21 protein and proliferating cell nuclearantigen(PCNA)in tumor tissues of 50 patients(Han 38,minority 12)with primary hepaticcarcinoma was detected byimmunohistochemistry(LSAB).RESULTS The positive frequency of p53,c-erbB-2,H-rasp21 and PCNA expression was46.0%(23/50),70.0%(35/50),68.0%(34/50)and 82.0%(41/50)in tumor tissues;4.0%(2/50),22.0%(11/50),64.0%(32/50)and 52.0%(26/ 50)in peritumors respectively and asignificant difference,except for H-rasp21,ofoncogene alteration was found(P<0.05)between tumor and non-tumorous tissues.Combined the three oncogenes alteration,26%(13/50)tumor tissues had positiveimmunoreactivity,but in peritumor and normallivers it was negative.The positive rate of p53,c-erbB-2 and H-rasp21 protein expression was39.5%(15/38),60.5%(23/38)and 39.5%(15/38)in tumors of Han patients;66.7%(8/12),100%(12/12)and 75.0%(9/12)in minoritiesrespectively,with statistical difference (P<0.05).CONCLUSION Overexpression of p53,c-erbB-2and H-rasp21 in human primary liver carcinoma isan important biomarker of genetic alteration.The different frequency of these oncogeneticchanges may reflect some environmental or/andethnic hereditary factors affecting the livercarcinogenesis.The special life style of Han,Uygur,Kazak and Mongolia nationalities inXinjiang may also be related to theetiopathogenesis of this disease. | Guo Yue Lin Zhao Lun Chen Cai Mo Lu Ying Li Xiao Jia Ping Rong Huang Department of Laboratory Medicine,Chinese PLA 474 Hospital,Urumqi 830011,Xinjiang Uygur Autonomic Region,China Department of Pathology,the 1st Teaching Hospital,Xinjiang Medical University,Urumqi 830054,Xinjiang Uygur Autonomic Region,China | 2000 | World Journal of Gastroenterology2000，6，2： | 40 |
| 16 | Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis显示文摘 | LI Xiang-dong YANG Yue-jin HAO Yong-chen YANG Ying ZHAO Jing-lin DOU Ke-fei GU Dong-feng | 2013 | Chinese Medical Journal2013，，9： | 35 |
| 17 | Prevalence, risk factors, clinical course, and outcome of acute kidney injury in Chinese intensive care units: a prospective cohort study显示文摘 | WEN Ying JIANG Li XU Yuan QIAN Chuan-yun LI Shu-sheng QIN Tie-he CHEN Er-zhen LIN Jian-dong AI Yu- hang WU Da-wei WANG Yu-shan SUN Ren-hua HU Zhen-jie CAO Xiang-yuan ZHOU Fa-chun HE Zhen-yang ZHOU Li-hua AN You-zhong KANG Yan MA Xiao-chun YU Xiang-you ZHAO Ming-yan XI Xiu-ming DU Bin | 2013 | Chinese Medical Journal2013，，23： | 40 |
| 18 | Analysis of Factors Associated with Death in Maintenance Hemodialysis Patients: A Multicenter Study in China显示文摘 | Kang-Kang Song De-Long Zhao Yuan-Da Wang Yong Wang Xue-Feng Sun Li-Ning Miao Zhao-Hui Ni Hong-Li Lin Fu-You Liu Ying Li Ya-Ni He Nian-Song Wang Cai-Li Wang Ai-Hua Zhang Meng-Hua Chen Xiao-Ping Yang Yue-Yi Deng Feng-Min Shao Shu-Xia Fu Jing-Ai Fang Guang-Yan Cai Xiang-Mei Chen | 2017 | Chinese Medical Journal2017，，8： | 39 |
| 19 | Chinese Stroke Center Alliance:a national effort to improve healthcare quality for acute stroke and transient ischaemic attack:rationale,design and preliminary findings显示文摘Background In June 2015,the Chinese Stroke Association(CSA)initiated the Chinese Stroke Center Alliance(CSCA)to establish the national hospital-based stroke care quality assessment and improvement platform.This article outlines its objectives,operational structure,patient population,quality improvement(QI)intervention tools,data elements,data collection methodology and current patient and hospital data.Methods The CSCA is a national,hospital-based,multicentre,voluntary,multifaceted intervention and continuous QI initiative.This multifaceted intervention includes stroke centre development,written care protocols,workshops and a monitoring/feedback system of evidencebased performance measures.The data coordinating centre of the CSCA resides at the China National Clinical Research Center for Neurological Diseases,Beijing Tiantan Hospital.results As of July 2017,1576 hospitals in China have contributed detailed clinical information to serve as a benchmark for the stroke care quality of 433264 patients with acute stroke/transient ischaemic attacks(TIA),including 352572(81.38%)acute ischaemic stroke,30362(7.01%)TIA,42080(9.71%)spontaneous intracranial haemorrhage,5505(1.27%)subarachnoid haemorrhage and 2745(0.63%)not specified stroke.Conclusion The CSCA programme is designed to establish a continuous national stroke registry and help healthcare providers develop stroke centres and treat patients in a consistent manner in accordance with accepted national guidelines and,ultimately,improve patient outcomes.It supports the CSA mission to reduce stroke burden in China. | Yongjun Wang Zixiao Li Yilong Wang Xingquan Zhao Liping Liu Xin Yang Caiyun Wang Hongqiu Gu Fuying Zhang Chunjuan Wang Ying Xian David Z Wang Qiang Dong Anding Xu Jizong Zhao Chinese Stroke Center Alliance investigators | 2018 | Stroke & Vascular Neurology2018，3，4： | 38 |
| 20 | Prevalence of HPV Infection And Cervical Intraepithelial Neoplasia And Attitudes towards HPV Vaccination among Chinese Women Aged 18-25 in Jiangsu Province显示文摘Objective:Few data are available on the epidemiology of HPV and cervical cancer among Chinese women younger than 25 years old.This study aimed to estimate the HPV infection rate and the prevalence of cervical intraepithelial neoplasia(CIN) in women aged 18-25,as well as their knowledge of and attitudes towards HPV vaccination.Methods:A population-based cervical cancer screening study was conducted on women aged 18-25 in Jiangsu province in 2008.Participants provided socio-demographic,reproductive and behavioral information and completed a survey about their knowledge of and attitudes towards HPV vaccination.Women then underwent a gynecologic exam to provide two cervical exfoliated cell samples for high risk HPV DNA testing and liquid-based cytology(LBC) as well as visual inspection with acetic acid(VIA).Women testing positive for any test were referred to colposcopy and biopsy.The gold standard for diagnosis of cervical lesions was directed or random biopsies.Results:Within the sample of 316 women,3.4% of them were diagnosed with CIN grade 2 or worse lesions and 17.1% were found to be positive for HPV DNA.Among these young women,extra-marital sexual behavior of them(OR=2.0,95%CI:1.1-3.8) or their husbands(OR=2.6,95%:1.4-4.7) were associated with an increased risk of HPV positivity.Although overall HPV awareness was low,after a brief educational intervention,98.4% reported they would electively receive HPV vaccination and would also recommend that their daughters be vaccinated.However,most urban and rural women reported their ideal maximum out-of-pocket contribution for HPV vaccination to be less than 500 RMB and 50-100 RMB,respectively.Conclusion:Our study indicates cervical disease burden is relatively high among sampled Chinese women aged 18-25.Appropriate educational interventions for female adolescents and strategies to subsidize vaccine costs are definitely needed to ensure the effectiveness of vaccination campaigns in China. | Shang-ying Hu Ying Hong Fang-hui Zhao Adam K. Lewkowitz Feng Chen Wen-hua Zhang O.in-jing Pan Xun Zhang Cindy Fei Hui Li You-lin Qiao | 2011 | Chinese Journal of Cancer Research2011，23，1： | 31 |
您所在的机构暂未开通此部分的功能，请联系管理员